Beijing Hotgen Biotech Co., Ltd. (SHA:688068)
China · Delayed Price · Currency is CNY 107.80
+4.69 (4.55%)
Jul 31, 2026, 3:00 PM CST
Beijing Hotgen Biotech Market Cap
Beijing Hotgen Biotech has a market cap or net worth of 9.48 billion as of July 31, 2026. Its market cap has decreased by -43.80% in one year.
Market Cap
9.48B
Enterprise Value
8.43B
Revenue
427.66M
Ranking
n/a
PE Ratio
n/a
Stock Price
107.80
ChartMarket Cap Chart
Since September 30, 2019, Beijing Hotgen Biotech's market cap has increased from 4.41B to 9.48B, an increase of 115.10%. That is a compound annual growth rate of 11.85%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 31, 2026 | 9.48B | -34.10% |
| Dec 31, 2025 | 14.39B | 159.78% |
| Dec 31, 2024 | 5.54B | 50.94% |
| Dec 29, 2023 | 3.67B | -34.53% |
| Dec 30, 2022 | 5.61B | -22.40% |
| Dec 31, 2021 | 7.22B | 197.90% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Chengzhi | 11.03B |
| Staidson (Beijing) BioPharmaceuticals | 10.68B |
| GemPharmatech | 10.38B |
| Hualan Biological Vaccine | 10.34B |
| Pacific Shuanglin Bio-pharmacy | 9.70B |
| Shanghai Medicilon | 9.41B |
| Nanjing Vazyme Biotech | 9.38B |
| Jiangxi Fushine Pharmaceutical | 9.14B |